title: IL-6 is a survival prognostic factor in renal cell carcinoma.
abstract: It has been reported that a high plasmatic concentration of interleukin-6 (IL-6) is correlated to a lack of response to immunotherapy in several malignancies, suggesting that IL-6 was either a marker of tumour aggressiveness or had only a predictive value of response to immunotherapy. To discriminate between these two possibilities, a retrospective study was performed in a series of 19 patients with metastatic renal cell carcinoma who did not respond to IL-2/IFNalpha/5-FU treatment. Serum levels of IL-6, C-reactive Protein (CRP), soluble IL-2-receptor (sIL-2R), M-CSF and neopterin were assayed before treatment. IL-6 showed a significant correlation with patients median survival time (P < 0.016), suggesting that serum concentration of IL-6 before treatment is a marker of tumour aggressiveness rather than a predictive parameter for an immunological response.
authors.affiliation: Clinique Urologique, Hôpital Cochin, Paris, France. n.thiounn@uro-cochin.asso.fr
authors.forename: N
authors.initials: N
authors.lastname: Thiounn
authors.forename: F
authors.initials: F
authors.lastname: Pages
authors.forename: T
authors.initials: T
authors.lastname: Flam
authors.forename: E
authors.initials: E
authors.lastname: Tartour
authors.forename: V
authors.initials: V
authors.lastname: Mosseri
authors.forename: M
authors.initials: M
authors.lastname: Zerbib
authors.forename: P
authors.initials: P
authors.lastname: Beuzeboc
authors.forename: L
authors.initials: L
authors.lastname: Deneux
authors.forename: W H
authors.initials: WH
authors.lastname: Fridman
authors.forename: B
authors.initials: B
authors.lastname: Debré
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D015415:Biomarkers; D001708:Biopterins / Q000031:analogs & derivatives / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000188:drug therapy / Q000401:mortality / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D015850:Interleukin-6 / Q000097:blood*; D007680:Kidney Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000401:mortality / Q000628:therapy; D016173:Macrophage Colony-Stimulating Factor / Q000097:blood; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D019798:Neopterin; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000097:blood; D011994:Recombinant Proteins; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000964:Antimetabolites, Antineoplastic; D015415:Biomarkers; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D015850:Interleukin-6; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D001708:Biopterins; D019798:Neopterin; D016173:Macrophage Colony-Stimulating Factor; D002097:C-Reactive Protein; D005472:Fluorouracil